Comparative Trial of the Safety and Immunogenicity of Quadrivalent (A, C, Y, W-135) Meningococcal Polysaccharide-Diphtheria Conjugate Vaccine Versus Quadrivalent Polysaccharide Vaccine in Two- to Ten-Year-Old Children

No abstract is available for this paper.

• Publication year

  2005

• Venue

  The Pediatric Infectious Disease Journal

• Publication date

  2005-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.inf.0000148928.10057.86PMID 15665711
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dosage Escalation, Safety and Immunogenicity Study of Four Dosages of a Tetravalent Meninogococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Infants

  2004cited by this paper
• Supplementary statement on conjugate meningococcal vaccines.

  2003cited by this paper
• Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults.

  2002cited by this paper
• Meningococcal disease.

  2001cited by this paper
• Invasive meningococcal disease in adolescents and young adults.

  2001cited by this paper
• Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England

  2001cited by this paper
• Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.

  2001cited by this paper
• Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines.

  2000cited by this paper
• The changing epidemiology of meningococcal disease in the United States, 1992-1996.

  1999cited by this paper
• Bacterial meningitis in the United States in 1995. Active Surveillance Team.

  1997cited by this paper
• Bacterial Meningitis in the United States in 1995

  1997cited by this paper
• Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group.

  1990cited by this paper
• Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine.

  1985cited by this paper
• Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children.

  1979cited by this paper
• Meningococcal Disease

  1974cited by this paper
• Prevention of meningococcal disease by group C polysaccharide vaccine.

  1970cited by this paper

• Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China

  2024cites this paper
• Analytical Challenges in Novel Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W, X)

  2024cites this paper
• Economic evaluation on meningococcal vaccination strategies among children under nine years of age in Zhejiang province, China

  2024cites this paper
• The Ongoing Journey of a Shigella Bioconjugate Vaccine

  2022cites this paper
• A phase II, single-center, randomized, double-blind, parallel control clinical study evaluating the immunogenicity and safety of a two-dose schedule of serogroups ACYW meningococcal polysaccharide conjugate vaccine.

  2022cites this paper
• Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines

  2021cites this paper
• Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020

  2020cites this paper
• Updated information on new coronavirus disease 2019 occurrence, drugs, and prediction of a potential receptor

  2020cites this paper
• Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016.

  2020cites this paper
• Recommended/Required Travel Vaccines

  2019cites this paper
• Practical Use of Meningococcal Vaccines—Whom and When to Vaccinate

  2019cites this paper
• Safety of a quadrivalent meningococcal conjugate vaccine in healthy subjects aged 9 months to 55 years in Vietnam

  2019cites this paper
• Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children.

  2018cites this paper
• Corrigendum

  2018cites this paper
• A Review of Research of Vaccine against Meningococcal Disease

  2018cites this paper
• 38 – Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines

  2018cites this paper
• Vaccine Science and Immunization Guideline

  2017cites this paper
• Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae

  2017cites this paper
• Vaccine-Preventable Diseases and the Vaccines That Prevent Them

  2017cites this paper
• Meningococcal Conjugate and Protein-Based Vaccines

  2016cites this paper
• Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants

  2016cites this paper
• Mucosal Immunization and Needle-Free Injection Devices

  2016cites this paper
• Fighting Neisseria meningitidis: past and current vaccination strategies

  2016cites this paper
• New Vaccines on the Horizon

  2016cites this paper
• Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant

  2015cites this paper
• Immunogenicity and Safety of Meningococcal C Conjugate Vaccine in Children and Adolescents Infected and Uninfected with HIV in Rio de Janeiro, Brazil

  2015cites this paper
• Evolving meningococcal immunization strategies

  2015cites this paper
• Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study

  2013cites this paper
• Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study

  2013cites this paper
• Prevention of Invasive Meningococcal Disease in the United States: Current State of the Art

  2013influential citation
• Glycoconjugate vaccines

  2013cites this paper
• 21 – Meningococcal vaccines

  2013cites this paper
• The Cost and Public Health Burden of Invasive Meningococcal Disease Outbreaks: A Systematic Review

  2013cites this paper
• Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease

  2013cites this paper
• Protein carriers of conjugate vaccines

  2013cites this paper
• Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers

  2012cites this paper
• Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology.

  2012cites this paper
• Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in 2- to 10-year-old Human Immunodeficiency Virus-infected Children

  2012cites this paper
• Safety and Immunogenicity of a Meningococcal Quadrivalent Conjugate Vaccine in Five- to Eight-Year-Old Saudi Arabian Children Previously Vaccinated with Two Doses of a Meningococcal Quadrivalent Polysaccharide Vaccine

  2012cites this paper
• A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years

  2012cites this paper
• Morbidity and Mortality Weekly Report

  2012cites this paper
• Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review.

  2011cites this paper
• CHAPTER 24 – Meningococcal Disease

  2011cites this paper
• Post-genomics of Neisseria meningitidis: an update

  2011cites this paper
• Meningococcal disease: The advances and challenges of meningococcal disease prevention

  2011cites this paper
• WITHDRAWN: Conjugate vaccines for preventing meningococcal C meningitis and septicaemia.

  2011cites this paper
• Meningococcal glycoconjugate vaccines

  2011cites this paper
• Bacterial outer membrane vesicles in disease and preventive medicine

  2011cites this paper
• Human coronavirus NL63: a clinically important virus?

  2011cites this paper
• Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.

  2011cites this paper
• Conjugate vaccines for preventing meningococcal C meningitis and septicaemia.

  2011cites this paper
• Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile

  2011cites this paper
• Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines.

  2010cites this paper
• Pediatric Vaccines on the Horizon

  2010cites this paper
• Travelers' protection against meningococcal disease: a new vaccine option.

  2010cites this paper
• Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.

  2010cites this paper
• Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.

  2010cites this paper
• Optimizing Protection Against Meningococcal Disease

  2010cites this paper
• STATEMENT ON PEDIATRIC TRAVELLERS: Committee to Advise on Tropical Medicine and Travel.

  2010cites this paper
• Meningococcal disease: is it a latent disease in Mexico?

  2010cites this paper
• Epidemiology and Meningococcal Serogroup Distribution in the United States

  2010cites this paper
• Bacterial post-genomics approaches for vaccines development

  2010cites this paper
• Continuing Impact of Infectious Diseases on Childhood Deaths in England and Wales, 2003–2005

  2010cites this paper
• Invasive pediatric Neisseria meningitidis infections.

  2009cites this paper
• Bacterial meningitis vaccines: Not just for kids

  2009cites this paper
• Meningococcal disease and prevention at the Hajj.

  2009cites this paper
• Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa.

  2009cites this paper
• Quadrivalent meningococcal conjugate vaccines.

  2009cites this paper
• Secreted proteins of Neisseria meningitidis protect mice against infection.

  2009cites this paper
• Postgenomics of Neisseria meningitidis: an update

  2009cites this paper
• Meningococcal disease: risk for international travellers and vaccine strategies.

  2008cites this paper
• Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease

  2008cites this paper
• Persistence of protection against invasive bacteria : memory B cell responses in infants after immunisation

  2008cites this paper
• Nueva vacuna antimeningocócica tetravalente en niños. ¿Un paso más?

  2008cites this paper
• Meningococcal tetravalent conjugate vaccine.

  2008cites this paper
• Meningococcal tetravalent conjugate vaccine

  2008cites this paper
• Immunization of Healthy Adults

  2008cites this paper
• Meningococcemia: epidemiology, pathophysiology, and management.

  2007cites this paper
• Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135. An Advisory Committee Statement (ACS).

  2007influential citation
• Use of Meningococcal Vaccines in the United States

  2007cites this paper
• Meningococcal vaccine in travelers

  2007cites this paper
• Postgenomics of Neisseria meningitidis for vaccines development

  2007cites this paper
• Genetic and Antigenic Analysis of Invasive Serogroup Y Neisseria meningitidis Isolates Collected from 1999 to 2003 in Canada

  2007cites this paper
• The prevention and management of infections in children with asplenia or hyposplenia.

  2007cites this paper
• Meningococcal disease associated with an acute post-streptococcal complement deficiency

  2007cites this paper
• Issues surrounding standardization of meningococcal group W135 serology.

  2007cites this paper
• Reconsideration of the Use of Meningococcal Polysaccharide Vaccine

  2007cites this paper
• Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines

  2007cites this paper
• Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine.

  2007cites this paper
• Routine vaccines across the life span, 2007.

  2007cites this paper
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

  2007cites this paper
• Summary of ‘Conjugate vaccines for preventing meningococcal C meningitis and septicaemia’

  2007cites this paper
• Postgenomics of Neisseria meningitidis for vaccines

  2007cites this paper
• 4.31 – Bacterial Carbohydrate-Based Vaccines

  2007cites this paper
• Vacinas na criança com imunodeficiência

  2007cites this paper
• Acute renal failure in cystic fibrosis

  2007cites this paper
• Cochrane review: Conjugate vaccines for preventing meningococcal C meningitis and septicaemia

  2007cites this paper
• Recent Advances in Immunization 2 nd Edition

  2006cites this paper
• The new meningococcal conjugate vaccine

  2006cites this paper
• The Possible Role of Transplacentally-Acquired Antibodies to Infectious Agents, With Molecular Mimicry to Nervous System Sialic Acid Epitopes, as Causes of Neuromental Disorders: Prevention and Vaccine Implications

  2006cites this paper